Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro

Biochemical and Biophysical Research Communications
Pamela J McLeanBradley T Hyman

Abstract

Geldanamycin (GA) is a naturally occurring benzoquinone ansamycin that induces heat shock protein 70 (Hsp70). GA has been shown to reduce alpha-synuclein induced neurotoxicity in a fly model of Parkinson's disease. We have previously shown that heat shock proteins can prevent alpha-synuclein aggregation and protect against alpha-synuclein induced toxicity in human H4 neuroglioma cells. Here, we hypothesize that GA treatment will reduce alpha-synuclein aggregation and prevent alpha-synuclein induced toxicity and we show that GA can induce Hsp70 in a time- and concentration-dependent manner in H4 cells. Pretreatment with 200nM GA 24h prior to transfection prevented alpha-synuclein aggregation and protected against toxicity. Treatment of cells with pre-existing inclusions with GA did not result in a reduction in the number of cells containing inclusions, suggesting that upregulation of Hsp70 is not sufficient to remove established inclusions. Similarly, Western blot analysis demonstrated that GA treatment could dramatically reduce both total alpha-synuclein and high molecular weight alpha-synuclein aggregates. Taken together, these data suggest that GA is effective in preventing alpha-synuclein aggregation and may represent a phar...Continue Reading

Citations

Mar 11, 2005·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Motomasa TanakaNobuyuki Nukina
Mar 7, 2009·Journal of Molecular Neuroscience : MN·Michael RiedelChristiane Richter-Landsberg
Jun 29, 2007·Expert Reviews in Molecular Medicine·Jean-Christophe Rochet
Oct 25, 2011·Nature Reviews. Cancer·Michael J DevineNicholas W Wood
Jan 20, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Chi-Chen LinMing-Derg Lai
Apr 26, 2008·The Journal of Biological Chemistry·Julie E TetzlaffPamela J McLean
Feb 11, 2009·The Journal of Biological Chemistry·Christine L KraghPoul Henning Jensen
Sep 30, 2010·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Karin M DanzerPamela J McLean
Nov 26, 2009·The Journal of Pharmacology and Experimental Therapeutics·Preeti PutchaPamela J McLean
Jul 13, 2011·Antimicrobial Agents and Chemotherapy·Fabienne LeidelMartin H Groschup
Jul 26, 2012·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Hemi DimantPamela J McLean
Jun 8, 2010·Molecular Neurodegeneration·Wenjie LuoGabriela Chiosis
Dec 10, 2013·Acta Neuropathologica Communications·Darius Ebrahimi-FakhariLara Wahlster
Sep 5, 2009·PloS One·Tiago F OuteiroBradley T Hyman
Jan 22, 2010·PloS One·Michael RiedelChristiane Richter-Landsberg
Feb 14, 2013·PloS One·Alice ZhaoEdward M Marcotte
Jan 6, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Gizem DonmezLeonard Guarente
Mar 16, 2011·Biochemistry Research International·Giuseppina TurturiciFabiana Geraci
Oct 30, 2014·Molecular Neurodegeneration·Simon MoussaudPamela J McLean
Nov 26, 2010·Cellular and Molecular Life Sciences : CMLS·Beatriz Alvarez-Castelao, José G Castaño
Feb 3, 2016·Frontiers in Neuroscience·Marion DelenclosPamela J McLean
Aug 16, 2014·The Anatomical Record : Advances in Integrative Anatomy and Evolutionary Biology·Daniel A SmithSanford I Bernstein
Jul 26, 2015·Journal of Molecular Neuroscience : MN·Nayereh ZareNader Maghsoudi
Jun 14, 2005·Brain Research. Molecular Brain Research·Kai KaarnirantaAntero Salminen
Mar 19, 2015·Expert Opinion on Therapeutic Targets·Simon MoussaudPamela J McLean
Oct 9, 2014·Annual Review of Pharmacology and Toxicology·William B PrattAndrew P Lieberman
Oct 7, 2005·Neurobiology of Aging·Kevin St P McNaught, C Warren Olanow
Jul 30, 2005·Journal of Molecular Biology·Todd R FlowerStephan N Witt
Aug 16, 2016·Cellular and Molecular Life Sciences : CMLS·Sandeep K Sharma, Smriti Priya
Sep 30, 2016·Expert Opinion on Investigational Drugs·Nóra TörökLászló Vécsei
Aug 22, 2008·Neurobiology of Aging·Evangelia EmmanouilidouKostas Vekrellis
Sep 2, 2016·Scientific Reports·Yi-Jheng PengChih-Yung Tang
Apr 22, 2017·Nature Reviews. Molecular Cell Biology·Florian H SchopfJohannes Buchner
Apr 24, 2007·Biochemical and Biophysical Research Communications·Tiago Fleming OuteiroAleksey G Kazantsev
Jul 29, 2008·Neurobiology of Disease·Sunitha RangarajuLucia Notterpek
Jan 11, 2014·Therapeutic Advances in Neurological Disorders·Daryl Rhys JonesPamela McLean
Sep 16, 2017·Parkinson's Disease·Erik L FriesenSuneil K Kalia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Alpha-Synuclein Aggregation

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.